Original Article
  

CD40L-CD40-Mediated Crosstalk between Eosinophils and Mast Cells Exacerbates Nasal Epithelial Barrier Dysfunction and Inflammatory Injury in Allergic Rhinitis

Abstract

The research intended to elucidate the synergistic effects of Eosinophils (Eos) and mast cells (MCs) on human nasal epithelial cells (HNEpCs) in the context of allergic rhinitis (AR), focusing on inflammation, tight junction protein expression, and DNA damage. Cell proliferation capacity was measured using the CCK-8 method, apoptosis was examined via the TUNEL assay, and inflammatory cytokine levels were assayed via ELISA. Western blotting evaluated the protein abundance of tight junction proteins (ZO-1, Occludin) and CD40L/CD40. Immunofluorescence was used to detect γH2AX (DNA damage) as well as subcellular ZO-1/Occludin distribution. Co-immunoprecipitation (Co-IP) was used to analyze the CD40L-CD40 interaction between Eos and MCs. Eos and MCs significantly reduced HNEpC viability and enhanced apoptosis, with the most pronounced effects in the AR+Eos+MC group. Inflammatory cytokine levels were markedly elevated in the Eos+MC and AR+Eos+MC groups, with the highest concentrations observed in the AR+Eos+MC group. Western blot and immunofluorescence analyses showed decreased expression of ZO-1 and Occludin in treatment groups compared to Control, along with a shift in their localization from the cell membrane to the cytoplasm. γH2AX expression, indicating DNA damage, was significantly elevated, with the highest levels observed in the AR+Eos+MC group. Co-immunoprecipitation (Co-IP) analysis confirmed enhanced CD40L–CD40 interaction involving Eos and MCs within the Eos+MC and AR+Eos+MC groups. Eosinophils and mast cells synergistically promote inflammation, disrupt the nasal epithelial barrier, and exacerbate DNA damage. The CD40L-CD40 pathway serves an essential function in their interaction, providing a potential therapeutic target for AR.

1. Nur Husna SM, Tan HT, Md Shukri N, Mohd Ashari NS, Wong KK. Allergic Rhinitis: A Clinical and Pathophysiological Overview. Front Med (Lausanne). 2022;9:874114.
2. Kang C, Li X, Liu P, Liu Y, Niu Y, Zeng X, et al. Tolerogenic dendritic cells and TLR4/IRAK4/NF-kappaB signaling pathway in allergic rhinitis. Front Immunol. 2023;14:1276512. Epub 2023/11/02.
3. Groger M, Bernt A, Wolf M, Mack B, Pfrogner E, Becker S, et al. Eosinophils and mast cells: a comparison of nasal mucosa histology and cytology to markers in nasal discharge in patients with chronic sino-nasal diseases. Eur Arch Otorhinolaryngol. 2013;270(10):2667-76.
4. Sanchez Santos A, Socorro Avila I, Galvan Fernandez H, Cazorla Rivero S, Lemes Castellano A, Cabrera Lopez C. Eosinophils: old cells, new directions. Front Med (Lausanne). 2024;11(3):1470381.
5. Costanzo G, Costanzo G, Del Moro L, Nappi E, Pelaia C, Puggioni F, et al. Mast Cells in Upper and Lower Airway Diseases: Sentinels in the Front Line. Int J Mol Sci. 2023;24(11).
6. Nur Husna SM, Tan HT, Md Shukri N, Mohd Ashari NS, Wong KK. Nasal Epithelial Barrier Integrity and Tight Junctions Disruption in Allergic Rhinitis: Overview and Pathogenic Insights. Front Immunol. 2021;12:663626.
7. Kuo WT, Odenwald MA, Turner JR, Zuo L. Tight junction proteins occludin and ZO-1 as regulators of epithelial proliferation and survival. Ann N Y Acad Sci. 2022;1514(1):21-33.
8. Siti Sarah CO, Md Shukri N, Mohd Ashari NS, Wong KK. Zonula occludens and nasal epithelial barrier integrity in allergic rhinitis. PeerJ. 2020;8:e9834.
9. Han M, Lee D, Lee SH, Kim TH. Oxidative Stress and Antioxidant Pathway in Allergic Rhinitis. Antioxidants (Basel). 2021;10(8).
10. Zhou A, Shi C, Fan Y, Zheng Y, Wang J, Liu Z, et al. Involvement of CD40-CD40L and ICOS-ICOSL in the development of chronic rhinosinusitis by targeting eosinophils. Front Immunol. 2023;14:1171308.
11. Ara A, Ahmed KA, Xiang J. Multiple effects of CD40-CD40L axis in immunity against infection and cancer. Immunotargets Ther. 2018;7:55-61.
12. Voynova E, Mahmoud T, Woods LT, Weisman GA, Ettinger R, Braley-Mullen H. Requirement for CD40/CD40L Interactions for Development of Autoimmunity Differs Depending on Specific Checkpoint and Costimulatory Pathways. Immunohorizons. 2018;2(1):54-66. Epub 2019/01/05. doi: 10.4049/immunohorizons.1700069.
13. Galdiero MR, Varricchi G, Seaf M, Marone G, Levi-Schaffer F, Marone G. Bidirectional Mast Cell-Eosinophil Interactions in Inflammatory Disorders and Cancer. Front Med (Lausanne). 2017;4:103. Epub 2017/08/10.
14. Liu S, Wu J, Meng L, Liu Y, Yu J, Yue J, et al. Piezo1-Induced Nasal Epithelial Barrier Dysfunction in Allergic Rhinitis. Inflammation. 2025;48(4):2824-36.
15. Chang W, He Y, Liu L. RGS1 induces nasal epithelial barrier dysfunction in allergic rhinitis by modulating NF-kappaB/AQP5 axis. Cytotechnology. 2025;77(5):164.
16. Kim EK, Choi EJ. Compromised MAPK signaling in human diseases: an update. Arch Toxicol. 2015;89(6):867-82.
17. Tang T, Cheng X, Truong B, Sun L, Yang X, Wang H. Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. Pharmacol Ther. 2021;219:107709.
18. Weinstein SF, Katial R, Jayawardena S, Pirozzi G, Staudinger H, Eckert L, et al. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol. 2018;142(1):171-7 e1.
19. Bachert C, Hellings PW, Mullol J, Hamilos DL, Gevaert P, Naclerio RM, et al. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy. 2020;75(1):148-57.
20. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. JAMA. 2016;315(5):469-79.
21. Karnell JL, Rieder SA, Ettinger R, Kolbeck R. Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond. Adv Drug Deliv Rev. 2019;141:92-103.
22. Samant M, Ziemniak J, Paolini JF. First-in-Human Phase 1 Randomized Trial with the Anti-CD40 Monoclonal Antibody KPL-404: Safety, Tolerability, Receptor Occupancy, and Suppression of T-Cell-Dependent Antibody Response. J Pharmacol Exp Ther. 2023;387(3):306-14.
Files
IssueArticles in Press QRcode
SectionOriginal Article(s)
Keywords
Allergic rhinitis eosinophils mast cells nasal epithelium CD40L-CD40 signaling inflammation DNA damage
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Deng J, Liu H, Zang Y, Wei Z, Yue X, Jin Z. CD40L-CD40-Mediated Crosstalk between Eosinophils and Mast Cells Exacerbates Nasal Epithelial Barrier Dysfunction and Inflammatory Injury in Allergic Rhinitis. Iran J Allergy Asthma Immunol. 2026;:1-11.